gtag('event', 'click', { 'event_category': 'PDF Download' });
was successfully added to your cart.



New drug approved for use in Scotland

CLDF welcomes today’s news that Odebixivat (brand name Bylvay) meets the Scottish Medicines Consortium definition of an ultra-orphan medicine, ie a medicine to treat an extremely rare condition.


The drug is already licensed for use in England for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients who are six months or older. Today’s announcement means that if your healthcare professional  thinks that odevixibat is the right medicine for your child, they should be able to have the treatment on the NHS in Scotland within the ultra-orphan pathway.


More information about Odebixivat and the ultra-orphan pathway is available here: AE odevixibat (Bylvay) SMC2411

Leave a Reply

© 2019 Children's Liver Disease Foundation. All Rights Reserved.